Bill Frezza, Columnist, Bio-IT World, General Partner at Adams Capital Management Bio and Contact Info
Chapters: (Advance the marker)
0:37 Will you rate the presidential candidates on science?
7:07 Let's just fund the top rate researchers
12:46 How do you measure success in the War on Cancer
15:48 Nothing has brought us more progress than the free market
17:57 What about the Manhattan Project?
22:14 How do we keep our edge in the world without strong science funding?
27:40 Who is going to fund life science start-ups?
31:55 BioLeap - designing drugs "de novo"
Bill Frezza is a venture capitalist and columnist at Forbes and Bio-IT World. As one can see from the name of his column, "The Skeptical Outsider," Bill is not shy about questioning the status quo. Today we get him to weigh in on the two presidential candidates and how the outcome of the election will affect science funding. Frezza is a free market advocate and feels that we are funding second and third rate research and creating a surplus of science PhD's. We talk about the War on Cancer and compare it to The Manhattan Project. At the end, Bill discusses the venture capital world and his own new venture, BioLeap.